The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Hematology/Oncology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Wed, 22 Jul 2026 20:08:50 GMT 2026 NEJM Group en-us 1440 In the ICU, a resident is surrounded by deaths, each one leaving him with a sense of emptiness. Then a Christmas tragedy highlights medicine’s privilege of bearing witness to love as well as death. https://www.nejm.org/doi/full/10.1056/NEJMp2516818?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2516818 Tristan Jones 2026-07-18 Love and Death Among patients with multiple myeloma, 7-year overall survival with 2 years of lenalidomide therapy was similar to that with indefinite therapy. Adverse events and second cancers were more common with indefinite therapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2600157?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2600157 Shaji Kumar, Susanna Jacobus, Adam Cohen, Matthias Weiss, Natalie Callander, Avina Singh, Terri Parker, Michael Green, Raymond Thertulien, Benjamin Parsons, Pankaj Kumar, Prashant Kapoor, Aaron Rosenberg, Elie Dib, Daniel Almquist, Jeffrey Zonder, Edward Faber, Zihan Wei, Kenneth Anderson, Sagar Lonial, Paul Richardson, Robert Orlowski, Lynne Wagner, S. Vincent Rajkumar 2026-07-16 Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma Multiple myeloma has undergone a therapeutic revolution at a pace nearly unmatched in oncology. Yet amid these advances, a key assumption in multiple myeloma therapy persists: more and longer treatment is better. The trial by Kumar and colleagues (ENDURANCE), reported in this issue of the Journal,1 ... https://www.nejm.org/doi/full/10.1056/NEJMe2604761?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2604761 Hira Mian, Luciano J. Costa 2026-07-16 Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma This review summarizes platelet-activating anti–platelet factor 4 disorders, including heparin-induced thrombocytopenia and related syndromes, highlighting diagnosis, antibody mechanisms, and treatment strategies. https://www.nejm.org/doi/full/10.1056/NEJMra2502459?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2502459 Theodore E. Warkentin, Andreas Greinacher 2026-07-13 Platelet-Activating Anti–Platelet Factor 4 Disorders After total hip or knee arthroplasty, aspirin alone was noninferior to rivaroxaban followed by aspirin in preventing symptomatic venous thromboembolism, with a similarly low risk of bleeding complications. https://www.nejm.org/doi/full/10.1056/NEJMoa2603649?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2603649 Sudeep Shivakumar, Davide Matino, David Zukor, Susan R. Kahn, George Vincent, Raman Mundi, Pascal-Andre Vendittoli, Mohammad Refaei, Eric Bohm, Michael Tanzer, Stéphane Pelet, Glen Richardson, James Powell, Rick Ikesaka, James Douketis, Sarah Ward, Paul Kim, Stephen Mann, Susan Pleasance, Jocelyn Cormier, Pantelis Andreou, Kara Matheson, Chris Theriault, Carol West, David Anderson, Peter L. Gross, the EPCAT III Trial Investigators* 2026-07-12 Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty A patient with type 1 diabetes received genetically modified allogeneic islets and no immunosuppression. Results obtained through 14 months support β-cell function and a lack of immune response against the allograft. https://www.nejm.org/doi/full/10.1056/NEJMc2604408?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2604408 Per-Ola Carlsson, Xiaomeng Hu, Hanne Scholz, Torbjörn Lundgren, Sofie Ingvast, Tim Scholz, Olof Eriksson, Per Liss, Irina Velikyan, Di Yu, Grigol Tediashvili, Tobias Deuse, Olle Korsgren, Sonja Schrepfer 2026-07-10 Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression Among patients with resected ALK-positive non–small-cell lung cancer, 2-year disease-free survival was higher with the ALK inhibitor ensartinib than with placebo. Grade 3 adverse events were more frequent with ensartinib. https://www.nejm.org/doi/full/10.1056/NEJMoa2518990?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2518990 Dongsheng Yue, Meijuan Huang, Pingping Song, Yuejun Chen, Bin Li, Junke Fu, Jianji Guo, Chao Cheng, Qixun Chen, Shidong Xu, Hongxu Liu, Fang Lv, Jian Hu, Ke Jiang, Weimin Mao, Bo Shen, Feng Ye, Jie Li, Xueying Zhang, Shiping Guo, Bentong Yu, Yuming Zhu, Ming Wu, Wei Zheng, Fang Chen, Zhengfu He, Yuansong Bai, Hua Xin, Keneng Chen, Naiquan Mao, Yu Zhang, Bo Wang, Lei Zhang, Xingwu Chen, Xinyu Mei, Liyun Miao, Runjie Wang, Gaofeng Li, Juntao Yao, Jun Zhao, Chun Chen, Junfeng Liu, Li Wei, Xiaolong Yan, Bo Jin, Xianling Liu, Zhidong Liu, Hui Tian, Wenqun Xing, Lin Yang, Di Ge, Xiangnan Li, Shanqing Li, Yongxiang Song, Aimin Zang, Dahai Zhang, Wu Zhuang, Zijin Liu, Xiaobin Yuan, Tao Fu, Zhilin Shen, Xiaojun Zhang, Qiuyue Cao, Luyang Zhao, Li Mao, Lieming Ding, You Lu, Changli Wang, the ELEVATE Study Group* 2026-07-09 Ensartinib in Resected ALK-Positive Non–Small-Cell Lung Cancer An ICU physician believed letting her father die at home meant comfort, dignity, control, family close by, and the quiet reassurance of hospice. But she didn’t realize what it would require of her family. https://www.nejm.org/doi/full/10.1056/NEJMp2517154?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2517154 Danielle D. DeCourcey 2026-07-09 For Those Left Behind A 42-year-old man with a recent stem-cell transplant presented with a 2-week history of urinary frequency and weak stream. Papules were seen on the penile shaft. Urethroscopy showed papillomatous lesions on the urethral mucosa. https://www.nejm.org/doi/full/10.1056/NEJMicm2603369?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2603369 Jung Hoon Bae, Hyong Woo Moon 2026-07-09 Condyloma Acuminata of the Urethra In patients with resected clear-cell renal-cell carcinoma, pembrolizumab plus belzutifan led to higher disease-free survival than pembrolizumab alone but an increased risk of grade 3 or higher adverse events. https://www.nejm.org/doi/full/10.1056/NEJMoa2518245?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2518245 Toni K. Choueiri, Robert J. Motzer, Jose A. Karam, Wesley Yip, Cristina Suárez, Dingwei Ye, Zhisong He, Christian Caglevic, Tom Ferguson, Yen-Hwa Chang, Carlos Rojas, Roberto Iacovelli, Yüksel Ürün, Elena Verzoni, Juan Carlos Vázquez Limón, Camillo Porta, Robert G. Uzzo, Jae Lyun Lee, Balaji Venugopal, Rana R. McKay, Hans Hammers, Hideaki Miyake, Jad Chahoud, Hong Liu, Joseph E. Burgents, Manish Sharma, Thomas B. Powles, the LITESPARK-022 Investigators* 2026-07-02 Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma Patients with shrinking cognitive bandwidth may feel their disability keenly in daily life, even if they can pass a controlled test of cognitive capacity. How should clinicians approach and care for them? https://www.nejm.org/doi/full/10.1056/NEJMp2600769?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2600769 Jan Stubberud 2026-07-02 The Invisible Load of Cognitive Symptoms In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days. https://www.nejm.org/doi/full/10.1056/NEJMoa2515820?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2515820 Brett L. Houston, Daniel I. McIsaac, Rodney H. Breau, Salmaan Kanji, Peter Greenstreet, Meghan Andrews, Sinziana Avramescu, Hema S. Bagry, Robert Balshaw, Jayesh Daya, Kaitlin Duncan, Christopher C. Harle, Eric Jacobsohn, Tina Kerelska, Marshall Pitz, Paul Komenda, Sarah McIsaac, Tim Ramsay, Tarit Saha, Alan Tinmouth, Angela Recio, Daniel Szoke, Marshall Tenenbein, Sarah Slagerman, Dayna Solvason, Robert Talarico, Dean A. Fergusson, Ryan Zarychanski 2026-06-25 Hospital Policy of Tranexamic Acid to Reduce Transfusion in Major Noncardiac Surgery Among 38 patients who received CAR T-cell therapy for refractory or relapsed B-cell lymphomas, lymphoma-free survival at 10 years was 32% for large B-cell lymphomas and 47% for follicular lymphoma. https://www.nejm.org/doi/full/10.1056/NEJMoa2518035?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2518035 Marco Ruella, Luca Paruzzo, Emeline R. Chong, Elise A. Chong, Daniel J. Landsburg, Sunita D. Nasta, Pooja Devi, Peter Michener, Federico Stella, Alberto Carturan, Ellen B. Napier, Vivianna M. Van Deerlin, Patrizia Porazzi, Bruce L. Levine, Noelle Frey, David L. Porter, Joseph A. Fraietta, Jakub Svoboda, Carl H. June, Stephen J. Schuster 2026-06-25 Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid just before the surgery. This failing is due not to a lack of high-quality scientific evidence on the overall safety, efficacy,... https://www.nejm.org/doi/full/10.1056/NEJMe2603105?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2603105 Michael F. Murphy, Ian Roberts 2026-06-25 TRACTION for Greater Surgical Use of Tranexamic Acid The EPA has decided to stop considering the monetary value of public health benefits in federal rulemaking related to air pollution. This decision could have profound health consequences. https://www.nejm.org/doi/full/10.1056/NEJMp2601300?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2601300 Arianne Teherani, Rupa Basu, Sheri Weiser 2026-06-25 When Health Costs No Longer Count — Air Pollution and EPA Rulemaking A rapid response to crizotinib after failure of chemotherapy in a patient with infantile fibrosarcoma with a TFG::MET fusion underscores the value of molecular profiling in atypical disease. This approach could enable limb sparing. https://www.nejm.org/doi/full/10.1056/NEJMc2518422?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2518422 Shampavi Sri Haran, Lucy Cain, Artur Darmanian, Michael Krivanek, Dale Wright, Wayne Nicholls, Martin Lowe, Luciano Dalla-Pozza, Bruce Goodwin, Jane McEniery, Kevin Hardin, Ashleigh Sullivan, Natacha Omer 2026-06-25 Response to Crizotinib in Infantile Fibrosarcoma with TFG::MET Gene Fusion Among patients with traumatic hemorrhage, prehospital whole-blood transfusion was not superior to standard transfusion with red-cell and plasma components in reducing the risk of death or massive transfusion. https://www.nejm.org/doi/full/10.1056/NEJMoa2516043?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2516043 Jason E. Smith, Rebecca Cardigan, Emily Sanderson, Laura Silsby, Claire Rourke, Ed B.G. Barnard, Peter Basham, Grazia Antonacci, Richard Charlewood, Nikki Dallas, Jane Davies, Elizabeth Goodwin, Annie Hawton, Cara Hudson, Joanne Lucas, Katie Keen, Richard M. Lyon, Brodie Nolan, Gavin D. Perkins, Viona Rundell, Laura Smith, Simon J. Stanworth, Anne Weaver, Tom Woolley, Laura Green, the SWiFT Trial Group* 2026-06-18 Prehospital Whole Blood in Traumatic Hemorrhage — A Randomized Controlled Trial Among patients with moderate or severe PTS, the addition of endovascular therapy to standard care resulted in less severe PTS and better quality of life at 6 months than standard care alone but with a higher risk of bleeding. https://www.nejm.org/doi/full/10.1056/NEJMoa2519001?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2519001 Suresh Vedantham, Susan R. Kahn, William A. Marston, Ido Weinberg, Akhilesh K. Sista, Elizabeth A. Magnuson, David J. Cohen, Suman M. Wasan, Mahmood K. Razavi, Samuel Z. Goldhaber, Kristen M. Sanfilippo, Anthony J. Comerota, Ezana M. Azene, Cassius Iyad Ochoa Chaar, Daniel A. Leung, K. Pallav Kolli, Sanjeeva P. Kalva, Nassir Rostambeigi, Ajinkya Desai, Kush R. Desai, Alfonso J. Tafur, Bhavraj Khalsa, Elaine Majerus, Borong Wang, Yang Wang, Patricia Nieters, Mary Clare Derfler, Angela Oliver, Cassandra Hardy, Riyaz Bashir, Ronald Winokur, Natalie Weger, Minhaj S. Khaja, Aditya Sharma, Naganathan Mani, Pavan Kavali, Siddhant Thukral, Leslie L. Lake, Kathryn Mikkelsen, Sameer Parpia, the C-TRACT Trial Investigators* 2026-06-18 Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood. https://www.nejm.org/doi/full/10.1056/NEJMoa2602167?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602167 Jason L. Sperry, Francis X. Guyette, Bryan A. Cotton, James F. Luther, Richard B. Utarnachitt, Matthew E. Kutcher, Brian J. Daley, Allan B. Peetz, Mayur B. Patel, Michael D. Goodman, Jeffrey A. Claridge, Nimitt Patel, Brian G. Harbrecht, Zain G. Hashmi, Ryan Zarychanski, Matthew D. Neal, Mark H. Yazer, Christian Martin-Gill, Laura E. Vincent, Ashley M. Harner, David E. Meyer, Andrew J. Latimer, Bryce R. Robinson, Catherine L. McKnight, William R. Hinckley, Keith R. Miller, Jan O. Jansen, Douglas Martin, Erin E. Fox, Bedda L. Rosario-Rivera, Stephen R. Wisniewski, the TOWAR Study Group* 2026-06-18 Prehospital Resuscitation with Type O Whole Blood for Trauma and Hemorrhage This review of the evolving management of differentiated thyroid cancer highlights overdiagnosis of low-risk disease, dynamic risk stratification, active surveillance or ablation, targeted therapies, and active patient involvement. https://www.nejm.org/doi/full/10.1056/NEJMra2416814?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2416814 Laszlo Hegedüs, Lori J. Wirth, R. Michael Tuttle 2026-06-18 Management of Differentiated Thyroid Cancer